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Abstract
Activation of spinal microglia contributes to aberrant pain responses associated with neuropathic
pain states. Endocannabinoids (ECs) are present in the spinal cord, and inhibit nociceptive
processing; levels of ECs may be altered by microglia which modulate the turnover of
endocannabinoids in vitro. Here, we investigate the effect of minocycline, an inhibitor of activated
microglia, on levels of the endocannabinoids anandamide and 2-arachidonoylglycerol (2-AG), and
the related compound N-palmitoylethanolamine (PEA), in neuropathic spinal cord. Selective spinal
nerve ligation (SNL) in rats resulted in mechanical allodynia and the presence of activated microglia
in the ipsilateral spinal cord. Chronic daily treatment with minocycline (30 mg/kg, ip for 14 days)
significantly reduced the development of mechanical allodynia at days 5, 10 and 14 post-SNL
surgery, compared to vehicle-treated SNL rats (P < 0.001). Minocycline treatment also significantly
attenuated OX-42 immunoreactivity, a marker of activated microglia, in the ipsilateral (P < 0.001)
and contralateral (P < 0.01) spinal cord of SNL rats, compared to vehicle controls. Minocycline
treatment significantly (P < 0.01) decreased levels of 2-AG and significantly (P < 0.01) increased
levels of PEA in the ipsilateral spinal cord of SNL rats, compared to the contralateral spinal cord.
Thus, activation of microglia affects spinal levels of endocannabinoids and related compounds in
neuropathic pain states.
Introduction
Since the discovery of the cannabinoid receptors CB1 and
CB2, and their endogenous ligands, there has been a rapid
growth of evidence that the cannabinoid receptor system
modulates the pathogenesis of various pain states. CB1
receptor agonists produce analgesic effects in models of
neuropathic pain that are mediated by both peripheral
and central sites of action [1]. However, activation of CB1
receptors in the central nervous system (CNS) is also asso-
ciated with adverse psychoactivity [2].
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Neuropathic pain responses are also attenuated by CB2
receptor agonists [3-5]. In contrast to the ubiquitous analge-
sic effects of CB1 receptor agonists, spinal administration of
CB2 receptor agonists only has inhibitory effects in neuro-
pathic rats and not sham-operated rats [6]. Importantly, the
spinal effects of CB2 agonists in neuropathic mice are absent
in CB2 knockout mice [4]. These functional data are sup-
ported by studies demonstrating an up-regulation of CB2
receptor mRNA and/or protein in the ipsilateral spinal cord
[7-9] and ipsilateral dorsal horn [10] of neuropathic rats,
compared to sham-operated rats. CB2 receptors in the spinal
cord were co-localised with activated microglia in neuro-
pathic rats [9], which is in keeping with earlier reports of CB2
receptor expression in microglia [11,12].
It is well established that spinal microglia undergo various
stages of morphological and immunophenotypic change
following nerve injury and contribute to the development of
neuropathic pain states [13]. Indeed, single injection of acti-
vated microglia into the spinal cord produces thermal hyper-
algesia in mice, one of the symptoms of neuropathic pain
[14]. The tetracycline derivative minocycline is neuroprotec-
tive in models of traumatic brain injury [15], Parkinson's dis-
ease and Alzheimer's disease [16]; effects which are largely
attributed to inhibition of microglia activation. Up-regula-
tion of activated microglia in the spinal cord of neuropathic
rats contributes to aberrant pain behaviour and plays an
important role in central sensitization. Minocycline attenu-
ates neuropathic pain behaviour and reduces microglia acti-
vation in the spinal cord [17-20]. In vitro, microglia are
capable of synthesising and catabolising endocannabinoids
[21,22], which play an important role in modulating nocic-
eptive responses. Thus, we hypothesized that the presence of
activated microglia in the spinal cord of neuropathic rats
may contribute to the reported increased levels of the endo-
cannabinoids anandamide (AEA) and 2-arachidonoylglyc-
erol (2-AG) in the spinal cord [23]. Herein, we demonstrate
that the inhibition of pain behaviour and microglia activa-
tion by chronic treatment with minocycline was associated
with decreased spinal levels of 2-AG, but not AEA. By con-
trast, we report a significant elevation of PEA in the spinal
cord of neuropathic rats treated with minocycline and dem-
onstrate differing rates of hydrolysis of AEA and PEA by
microglia BV-2 cells, which supports the notion that micro-
glia differentially modulate levels of endocannabinoids in
pathological states. Our data implicate a contribution of
PEA, which has been shown to be neuroprotective in a
model of focal cerebral ischemia [24], to the analgesic effects
of minocycline in neuropathic rats.
Results
Minocycline attenuates mechanical allodynia induced by 
spinal nerve ligation
Chronic vehicle treatment did not alter the ipsilateral or
contralateral paw withdrawal thresholds (PWTs) in sham-
operated rats (data not shown). By contrast, SNL rats
chronically treated with vehicle had a significantly (P <
0.001) lower ipsilateral PWT, compared to the PWT of the
contralateral hindpaw of SNL rats and ipsilateral hindpaw
of sham-operated rats (data not shown), consistent with
the development of mechanical allodynia in these rats
(Fig 1). Chronic daily treatment with minocycline (30
mg/kg, ip for 14 days) starting at 1 hr before SNL surgery
significantly reduced the development of mechanical allo-
dynia at days 5, 10 and 14 post-surgery compared to vehi-
cle-treated SNL rats (Fig 1). Chronic minocycline
treatment (30 mg/kg, ip) in sham-operated rats did not
alter ipsilateral or contralateral PWT (data not shown).
Effects of chronic minocycline treatment on spinal glial 
cell proliferation
SNL surgery significantly increased OX-42 immunoreac-
tivity in the L4-L6 sections of ipsilateral spinal cord of
chronic vehicle-treated rats, compared to the contralateral
spinal cord, indicative of spinal microglia activation (Fig
2, OX-42 immunoreactivity, ipsilateral-vehicle, 30.2 ±
0.5; contralateral-vehicle, 17.0 ± 0.3). Chronic minocy-
cline treatment (30 mg/kg, ip) significantly attenuated
OX-42 immunoreactivity in the ipsilateral (P < 0.001) and
contralateral (P < 0.01) spinal cord of SNL rats, compared
to vehicle controls (Fig 2). Thus, effects of minocycline
treatment on neuropathic pain behaviour were associated
with decreased levels of a marker for activated microglia in
the ipsilateral spinal cord of SNL rats. Nevertheless, levels
of OX-42 in the ipsilateral spinal cord of SNL rats treated
with minocycline were still elevated compared to the con-
Chronic treatment with minocycline significantly attenuates  spinal nerve ligation-induced reduction in mechanical paw  withdrawal threshold Figure 1
Chronic treatment with minocycline significantly 
attenuates spinal nerve ligation-induced reduction in 
mechanical paw withdrawal threshold. Minocycline 
(Mino, 30 mg/kg, ip) or vehicle (Veh, sterile water) was 
injected daily for 14 days and paw withdrawal threshold of 
the ipsilateral (Ipsi) and contralateral (Contra) hindpaw were 
measured using von Frey filaments (sham data not shown for 
clarity of figure). Data were analysed using 2-way ANOVA 
followed by Bonferroni's post-hoc tests, and are expressed 
as mean (± SEM, n = 6 rats/group). ** P < 0.01, *** P < 0.001 
vs contralateral paw; δ P < 0.05, δδ P < 0.01, δδδ P < 0.001 vs 
vehicle-ipsilateral paw.
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tralateral spinal cord of minocycline-treated SNL rats
(total: ipsilateral-minocycline, 14.9 ± 1.3; contralateral-
minocycline, 6.5 ± 0.7).
Minocycline treatment alters spinal levels of 
endocannabinoids and related fatty acid ethanolamides in 
spinal nerve ligated rats
In SNL rats with chronic vehicle treatment, levels of AEA
were significantly increased (P < 0.01) in the ipsilateral
spinal cord, compared to the contralateral spinal cord
(Table 1). Following chronic minocycline treatment in
SNL rats, levels of AEA in the ipsilateral spinal cord were
also elevated, compared to the contralateral spinal cord
(Fig 3). The elevated ipsilateral levels of AEA in minocy-
cline-treated rats were not different from the levels in
vehicle-treated SNL rats.
There were no significant differences in levels of OEA in
the ipsilateral and contralateral spinal cord of vehicle-
treated SNL rats (Table 1). Levels of OEA in ipsilateral and
contralateral spinal cord of SNL rats were unaltered by
minocycline treatment (Fig 3).
By contrast, chronic minocycline treatment of SNL rats
had a marked impact on levels of 2-AG and PEA in the
ipsilateral spinal cord, compared to the contralateral spi-
nal cord (Fig. 3) and the ipsilateral spinal cord from vehi-
cle-treated animals. In vehicle-treated SNL rats, levels of
Chronic minocycline treatment attenuates the spinal nerve-ligation induced increase in OX-42 immunoreactivity (ir) in the  lumbar spinal cord Figure 2
Chronic minocycline treatment attenuates the spinal nerve ligation-induced increase in OX-42 immunoreac-
tivity (ir) in the lumbar spinal cord. Vehicle (A, B, C, sterile water) or minocycline (D, E, F, 30 mg/kg, ip) was injected daily 
for 14 days and spinal cords dissected and processed for immunohistochemical detection of OX-42ir at the level of L4 (A-a" 
and D-d"), L5 (B-b" and E-e") and L6 (C-c" and F-f"). High magnification images of the dorsal area used for OX-42ir signal quan-
tification are also shown. Histograms (G-I) showing effects of minocycline or vehicle in L4-L6 spinal cord OX-42ir (white bars: 
ipsilateral side; black bars: contralateral side) are shown at the bottom. Data are expressed as mean ± SEM (n = 12 sections 
from 4 rats per group). Data were analysed using Kruskal Wallis non-parametric test followed by Dunn's multiple comparison 
posthoc analysis, * P < 0.05, ** P < 0.01, *** P < 0.001 vs ipsilateral-veh, # P < 0.05, ## P < 0.01 vs contralateral-vehicle. Scale 
bars: F = 1 mm (applies to A-F); f' = 100 μm (applies to a'-f' and a"-f").Molecular Pain 2009, 5:35 http://www.molecularpain.com/content/5/1/35
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PEA were decreased (P < 0.01) in the ipsilateral spinal
cord, compared to contralateral spinal cord (Table 1).
However levels of PEA were increased (P < 0.01) in the
ipsilateral spinal cord (31.59 ± 5.61 nmol/g) of minocy-
cline-treated SNL rats compared to their contralateral spi-
nal cord (5.01 ± 0.48 nmol/g) (Fig 3). Although there
were no significant differences in levels of 2-AG in the
ipsilateral and contralateral spinal cord of vehicle-treated
SNL rats (Table 1), levels of 2-AG were significantly
decreased (P < 0.01) in the ipsilateral spinal cord (4.53 ±
0.93 nmol/g) compared to contralateral spinal cord
(47.66 ± 4.38 nmol/g) of minocycline treated SNL rats
(Fig 3).
Chronic minocycline treatment of sham-operated rats did
not significantly alter levels of AEA, OEA or PEA in the
ipsilateral spinal cord, compared to the contralateral spi-
nal cord (Fig 3). By contrast, levels of 2-AG in the ipsilat-
eral spinal cord of minocycline treated sham-operated rats
were significantly (P < 0.05) lower than levels in the con-
Effects of chronic intraperitoneal dosing of minocycline (Mino, 30 mg/kg) or vehicle (Veh, sterile water) on the levels of endo- cannabinoids (A, B) and related fatty acid ethanolamides (C, D) in the ipsilateral spinal cord of spinal nerve ligated (SNL) or  sham-operated rats Figure 3
Effects of chronic intraperitoneal dosing of minocycline (Mino, 30 mg/kg) or vehicle (Veh, sterile water) on the 
levels of endocannabinoids (A, B) and related fatty acid ethanolamides (C, D) in the ipsilateral spinal cord of 
spinal nerve ligated (SNL) or sham-operated rats. Data were analysed using Mann-Whitney nonparametric test and are 
expressed as a mean percentage of contralateral levels ± SEM (n = 5 – 6 rats/group). * P < 0.05, ** P < 0.01 vs contralateral 
paw. AEA, anandamide; 2-AG, 2-arachidonoylglycerol; PEA, N-palmitoylethanolamine; OEA, N-oleoylethanolamine.
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Table 1: Levels of endocannabinoids and related fatty acid ethanolamides measured in the ipsilateral and contralateral spinal cord of 
spinal nerve ligated (SNL) rats treated chronically with vehicle (sterile water, ip, 2 ml/kg) daily for 14 days.
AEA (pmol/g) 2-AG (nmol/g) OEA (nmol/g) PEA (nmol/g)
SNL – vehicle Ipsilateral 65.86 ± 6.92** 52.21 ± 4.47 1.72 ± 0.15 4.20 ± 0.39**
Contralateral 28.42 ± 0.86 54.40 ± 4.02 1.43 ± 0.08 8.80 ± 0.97
Data were analysed using Mann-Whitney non-parametric tests and are expressed as mean ± SEM mol/g (n = 5–6 rats per group). ** P < 0.01 vs 
contralateral spinal cord. AEA, anandamide; 2-AG, 2-arachidonoylglycerol; PEA, N-palmitoylethanolamine; OEA, N-oleoylethanolamine.Molecular Pain 2009, 5:35 http://www.molecularpain.com/content/5/1/35
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tralateral spinal cord (Fig 3; ipsilateral: 39.79 ± 4.38
nmol/g, contralateral: 62.61 ± 7.91 nmol/g).
Levels of ECs and related compounds in the contralateral
spinal cord of SNL rats treated with minocycline were
compared to levels in the contralateral spinal cord of SNL
rats treated with vehicle. Although levels of AEA in the
contralateral spinal cord of minocycline treated SNL rats
were not significantly different to levels in the contralat-
eral spinal cord of vehicle-treated SNL rats, there was a
trend towards an increase in the minocycline treated
group (53.72 ± 2.33 pmol/g vs  28.42 ± 0.86 pmol/g
respectively). Levels of OEA in the contralateral spinal
cord of minocycline-treated rats were comparable to levels
in the contralateral spinal cord of vehicle-treated rats
(1.51 ± 0.13 nmol/g vs 1.43 ± 0.08 nmol/g). In contrast to
the marked effects of minocycline treatment on levels of
PEA and 2-AG in the ipsilateral spinal cord of SNL rats,
this treatment did not significantly influence levels of PEA
and 2AG in the contralateral spinal cord. There were no
significant differences between levels of 2-AG or PEA in
contralateral spinal cord of minocycline-treated SNL rats
compared to vehicle-treated SNL rats (2-AG, 47.66 ± 4.38
nmol/g vs 54.40 ± 4.02 nmol/g; PEA, 5.01 ± 0.48 nmol/g
vs 8.80 ± 0.97 nmol/g).
Microglial differentially hydrolyse AEA and PEA
Our in vivo data demonstrate that neuropathic pain has a
differential effect on the levels of AEA and PEA in the spi-
nal cord, which may reflect the presence of microglia in
the spinal cord. Here, we investigated the hypothesis that
microglia have a differential effect on the hydrolysis of
AEA and PEA, which may account for our in vivo observa-
tions in neuropathic rats. We report marked differences in
the time courses for PEA and AEA hydrolysis in intact BV-
2 microglial cells (Fig 4.) Specifically, the capacity for
hydrolysis of AEA by the BV-2 cells was limited, in that,
after 10 minutes, there was no further metabolism of AEA,
as shown by the plateau in accumulation of water-soluble
product. In marked contrast, the hydrolysis of PEA contin-
ued for at least 30 minutes (Fig 4).
Discussion
Two weeks following peripheral nerve injury, levels of the
endocannabinoid AEA are markedly elevated in the ipsi-
lateral spinal cord of neuropathic rats, whereas levels of
the related anti-inflammatory compound PEA are signifi-
cantly decreased. By contrast levels of 2-AG and OEA in
the ipsilateral spinal cord of neuropathic rats are unal-
tered compared to the contralateral spinal cord. Inhibi-
tion of microglia activation, by chronic minocycline
treatment, significantly altered pain behaviour and levels
of 2-AG and PEA in the ipsilateral spinal cord of neuro-
pathic rats without affecting levels of AEA or OEA.
Two weeks following peripheral nerve injury we observed
a significant elevation in levels of activated microglia
(increased OX-42 labelling) and AEA in the ipsilateral spi-
nal cord, compared to the contralateral spinal cord. By
contrast, levels of AEA in the ipsilateral spinal cord of
sham operated rats were unaltered compared to the con-
tralateral spinal cord. In the same group of neuropathic
rats, levels of PEA were significantly decreased in the ipsi-
lateral spinal cord, compared to the contralateral spinal
cord. Levels of PEA were unaltered in the ipsilateral spinal
cord of sham operated rats, compared to the contralateral
spinal cord. The elevation in levels of AEA in neuropathic
rats is consistent with an earlier report that levels of AEA
are elevated 3 fold in the whole lumbar spinal cord at 3
and 7 days following chronic constriction injury of the sci-
atic nerve [23]. This previous study also reported
decreased levels of PEA in the whole lumbar spinal cord at
3 days, but not 7 days, following chronic constriction
injury of the sciatic nerve. Although our findings are con-
sistent with the previous report of increased levels of AEA
in the lumbar spinal cord, our data highlight the impor-
tance of selective ipsilateral changes in levels of ECs and
related compounds which is not unexpected given the
unilateral nature of the pain behaviour.
Our data demonstrating a differential effect of peripheral
nerve injury on levels of AEA versus PEA in the ipsilateral
spinal cord suggest that their metabolism can be regulated
independently in vivo, in keeping with the discovery of dif-
ferent biosynthetic pathways for AEA and PEA in the brain
[25] and evidence of independent signalling pathways in
a microglia cell line (BV-2 cells) [26].
Despite the increased levels of activated microglia in the
ipsilateral spinal cord, compared to the contralateral spi-
nal cord, of neuropathic rats we did not observe any
Time course of hydrolysis of AEA (anandamide) and PEA (N- palmitoylethanolamine) in BV2 microglial cells Figure 4
Time course of hydrolysis of AEA (anandamide) and 
PEA (N-palmitoylethanolamine) in BV2 microglial 
cells. Data are means ± SEM of six independent experiments 
conducted in triplicate.
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changes in levels of 2-AG in the ipsilateral spinal cord of
neuropathic rats. In vitro studies have shown a role of 2-
AG in CB2 receptor mediated migration of microglia [27]
and proliferation of microglia [21]. In the present study
we did not determine whether levels of 2-AG were ele-
vated at earlier timepoints, which may have contributed
to the recruitment of microglia to the site of spinal injury.
This does, however, seem unlikely as levels of 2-AG were
unaltered in the whole lumbar spinal cord at 3 days fol-
lowing peripheral nerve injury [23].
Chronic daily treatment with minocycline significantly
attenuated the development of mechanical allodynia and
the associated increase in activated microglia, in the L4 -
L6 region of the ipsilateral spinal cord in neuropathic rats.
These data are consistent with previous studies of the
effects of minocycline on microglia activation and neuro-
pathic pain behaviour [17,28]. Levels of OX-42 labelling
in the contralateral spinal cord of vehicle-treated SNL rats
were higher than those in the contralateral spinal cord of
minocycline-treated SNL rats, consistent with the bilateral
activation of microglia in the spinal cord following
peripheral nerve injury [29] and indicates that minocy-
cline treatment modulates this bilateral activation of
microglia. Nevertheless, we did not observe any changes
in paw withdrawal threshold of the contralateral hindpaw
which indicates the absence of mechanical allodynia.
Minocycline treatment did not significantly alter mechan-
ical allodynia until day 5 post SNL surgery, there was how-
ever a trend towards an effect on day 3. These data
corroborate previous studies reporting that the prolifera-
tion of microglia peaks at around 3 days following nerve
injury, however this does vary slightly depending on the
model studied [30]. The lack of effect of minocycline on
mechanical allodynia on the first day after SNL surgery
may reflect a delayed onset of action of minocycline [31].
Alternatively, microglia may not make a substantial con-
tribution to the mechanical allodynia at this very early
timepoint and, therefore, this treatment is unable to alter
responses. It is feasible that the mechanical allodynia
observed at day 1, and to some extent day 3, following
SNL surgery is mediated, at least in part, by a transient
post-surgical pain.
The effects of minocycline have been largely attributed to
the inhibition of microglia [32], but effects on neuronal
function in vitro should be borne in mind [31]. The inte-
grated nature of in vivo studies makes it difficult to disso-
ciate direct, versus indirect, effects of minocycline on
microglia function and how this relates to levels of ECs
and related compounds in neuropathic rats. It is esti-
mated that, in vitro at least, microglia produce 20-fold
more endocannabinoids than neurones or astrocytes
[27,33] and primary microglia inactivate both AEA and 2-
AG [34], suggesting that changes in the levels of activated
microglia in the spinal cord, despite their lower abun-
dance compared with neurones and other glia, could have
a significant effect on whole tissue endocannabinoid con-
tent. Our data are consistent with this notion, indeed inhi-
bition of microglia activation was associated with a
significant decrease in levels of 2-AG in the ipsilateral spi-
nal cord of neuropathic rats, compared to the contralat-
eral spinal cord. These data suggest that activated
microglia may contribute to the biosynthesis of 2-AG in
neuropathic rats, which is consistent with previously
described production of 2-AG by microglia in vitro
[21,27,34], and provide indirect evidence for microglia
modulation of 2-AG turnover in vivo.
We have identified major differences in the effects of
microglial inhibition on levels of AEA and PEA in neuro-
pathic rats, which suggest that there is divergence in the
biosynthesis/catabolism of these N-acylethanolamines by
microglia. Our data suggest that activated microglia play a
major role in modulating levels of PEA, but not AEA or
OEA, in the spinal cord of neuropathic rats. Given that in
vitro studies using BV-2 cells suggest that microglia pro-
duce 1.5 fold more PEA than 2-AG [26], we hypothesised
that the effects of inhibiting activated microglia on levels
of PEA reflected a role of microglia in the hydrolysis of
PEA.
To investigate whether differential catabolism of PEA and
AEA by microglia may account for our in vivo data, we
studied their rates of hydrolysis in intact BV-2 microglia
cells. We demonstrate for the first time that the hydrolysis
of PEA is sustained, whereas hydrolysis of AEA is tran-
sient, in BV-2 cells. These in vitro findings are consistent
with our in vivo data, and suggest that the presence of acti-
vated microglia in the spinal cord of neuropathic rats con-
tributes to the decreased spinal levels of PEA as a result of
the sustained hydrolysis of PEA versus AEA. Conversely,
inactivation of spinal microglia by minocycline would
result in a decreased microglial component of PEA hydrol-
ysis and the observed increase in levels of PEA in the spi-
nal cord of neuropathic rats treated with minocycline. The
differential hydrolysis of PEA and AEA by BV-2 cells sug-
gests that distinct enzymatic activities may be responsible
for AEA and PEA catabolism in microglia. Indeed, micro-
glial cells express both fatty acid amide hydrolase and
monoacylglycerol lipase, as well as other activities includ-
ing a PEA hydrolase with a distinct pharmacological pro-
file [22].
When considering the behavioural phenotype of minocy-
cline-treated neuropathic rats versus vehicle-treated rats,
the analgesia seen in the minocycline-treated rats may be
mediated by the increased levels of AEA observed in neu-
ropathic rats. It is unlikely that 2-AG contributes to the
changes in behavioural allodynia, as the marked loss of 2-
AG could be expected to exacerbate allodynia. The most
prominent effect of minocycline was the significant eleva-Molecular Pain 2009, 5:35 http://www.molecularpain.com/content/5/1/35
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tion of ipsilateral PEA in minocycline-treated neuropathic
rats, compared to vehicle treated neuropathic rats. PEA
has been shown to attenuate neuropathic pain behaviour
[35,36]. Although a role of cannabinoid CB2 receptors in
the effects of PEA was initially proposed [37,38] this was
then discounted [39]. Furthermore, the antinociceptive
profile of PEA differs from the broad spectrum analgesia
produced by systemically administered CB2 receptor ago-
nists [40]. PEA has well described anti-inflammatory
effects and has been shown to be neuroprotective [24].
PEA activates the nuclear receptor peroxisome prolifera-
tor-activated receptor-α, which mediates the analgesic
effects of PEA [41]. Inhibitory effects of PEA in neuro-
pathic rats are also mediated by PPARγ receptors [36]. Our
data suggest that the contribution of PEA to the neuropro-
tective effects of minocycline warrants further investiga-
tion.
In conclusion, we have shown that the analgesic effects
produced by minocycline treatment are associated with
marked changes in levels of 2-AG and PEA and activated
microglia in the spinal cord of neuropathic rats. Our data
provide evidence for a role of activated microglia in the
control of levels of endocannabinoids and related com-
pounds in vivo.
Methods
All experiments were carried out in accordance with the
UK Home Office Animals (Scientific Procedures) Act
(1986). Experiments were performed on 32 male Sprague
Dawley rats (CRUK) in the light period of a 12 hr light/
dark cycle. Animals had free access to food and water and
were group-housed throughout the experiments. Rats
were divided into 4 experimental groups comprising of
sham-operated and SNL rats, treated with either vehicle or
minocycline.
Model of neuropathic pain: Spinal nerve ligation
The spinal nerve ligation model of neuropathic pain was
used in this study. Spinal nerves L5-L6 were ligated
according to the procedures described by [42]. Male
Sprague Dawley rats (101 – 135 g) were anaesthetised
using isoflurane (3% induction, 1–1.5% maintenance in
33% O2/67% N2O) and placed in a prone position. A
midline incision was made at the L3-S2 level and the left
paraspinal muscles at L4-S2 level were separated from spi-
nal processes. Part of the L6 transverse process was
removed with fine rongeurs and the L4-L6 nerves identi-
fied. The L5-L6 spinal nerves were isolated and tightly
ligated (one suture per nerve) distal to the dorsal root gan-
glia and proximal to the sciatic nerve formation with 6-0
silk. The wound was closed in two layers using absorbable
sutures and wound clips, following complete haemosta-
sis. A similar procedure was performed for the sham sur-
gery, except spinal nerves were not ligated. Post-surgery,
the sham-operated and the SNL rats were group-housed
(5 rats per cage) and their posture and behaviour were
closely monitored for 48 hours.
Drug treatment protocol
Effects of chronic intraperitoneal (ip) injections of mino-
cycline (Sigma, UK, 30 mg/kg, n = 16) or vehicle (2 ml/kg
sterile water, n = 16) on mechanical allodynia were meas-
ured over 14 days post-surgery in sham-operated and SNL
rats. Minocycline (30 mg/kg, ip) or vehicle was injected
into rats 1 hour before sham- or SNL surgery and subse-
quently daily for 14 days, approximately 15 hours prior to
behavioural testing.
Behavioural testing
From post-operative day 1 onwards (days 1, 3, 5, 7, 10
and 14), behavioural testing was performed to assess the
development of mechanical allodynia, all testing was car-
ried out between 8 and 11 am. Rats were placed in perspex
cubicles with wire mesh grid floors and allowed to accli-
matise prior to behavioural testing. Mechanical sensitivity
of the ipsilateral and contralateral hind paw was assessed
by measuring the paw withdrawal threshold (PWT) at
which foot withdrawal to normally innocuous mechani-
cal punctate stimuli was observed. Stimuli were delivered,
from below, to the plantar surface of the foot using 0.2, 2,
4, 6, 8, 10 and 15 g von Frey hair stimuli for a maximum
of 5 seconds per application. Each trial consisted of the
application of a single von Frey hair, starting with a 4 g
stimulus, and either increasing or decreasing in intensity
until the PWT was observed, with the stimulus either side
of the withdrawal weight subsequently repeated. The paw
withdrawal threshold was recorded as the lowest von Frey
stimulus to elicit a response.
Measurement of endocannabinoids and related 
compounds
On post-operative day 15, approximately 15 hours after
the last injection of minocycline (30 mg/kg, ip) or vehicle,
rats were decapitated prior to a standardised and rapid
dissection of the ipsilateral and contralateral lumbar (L4-
L6) spinal cord. The whole process was complete within 3
minutes and samples were placed immediately on dry ice
and then stored at -80°C to minimise post-mortem
changes in levels of endocannabinoids (ECs) and related
compounds. A validated lipid extraction method [43] was
employed for measurement of AEA and 2-AG and related
compounds, PEA and N-oleoylethanolamine (OEA). In
brief, tissue was homogenised in an ethyl acetate/hexane
mixture with internal standards (0.42 nmol d8-AEA, 1
nmol d8-2-AG), followed by repeated centrifugation and
supernatant layer collection stages. Solid phase extraction
was subsequently performed to purify samples. Simulta-
neous measurement of ECs and related compounds was
then performed using liquid chromatography-tandem
mass spectrometry (LC-MS/MS). Analysis was carried out
on an Agilent 1100 system (Agilent Technologies, Waldb-Molecular Pain 2009, 5:35 http://www.molecularpain.com/content/5/1/35
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runn, Germany) coupled to a triple quadrupole Quattro
Ultima MS (Waters, Manchester, UK) recording in electro-
spray positive mode. Analytes were separated chromato-
graphically on a HyPurity Advance C8 column and pre-
column (100 × 2.1 mm internal diameter, 3 μm particle
size; Thermo Fisher Scientific, Runcorn, UK) with a
mobile phase flow rate of 0.3 ml/min. A gradient elution
was used, with mobile phases consisting of A (water, 1 g/
L ammonium acetate, 0.1% formic acid) and B (ace-
tonitrile, 1 g/L ammonium acetate, 0.1% formic acid).
Samples were injected from a cooled auto sampler main-
tained at 4°C. Multiple reaction monitoring of individual
compounds, using specific precursor and product mass to
charge (m/z) ratios allowed simultaneous measurement of
AEA, 2-AG, PEA and OEA.
Quantification of microglia
In a separate series of experiments, groups of vehicle-
treated SNL rats or minocycline-treated SNL rats (n = 4 per
group) were prepared for immunohistochemical studies
of microglia activation. The development of mechanical
allodynia in vehicle-treated SNL rats and the effect of
minocycline treatment on mechanical allodynia were
consistent with behavioural changes observed in vehicle-
treated SNL and minocycline-treated SNL rats employed
for measurement of levels of ECs. On post-operative day
15, rats were transcardially perfused with saline (0.9% w/
v sodium chloride) followed by paraformaldehyde (PFA,
Sigma, UK, 4% w/v) in phosphate-buffered saline (PBS,
3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135
mM NaCl, pH 7.4) under terminal anaesthesia induced by
pentobarbital sodium (Euthetal®, Merial Animal Health
Ltd, UK, 800 mg/kg, ip). The spinal cord was dissected
and stored in PFA for approximately 2 hrs at 4°C, and
then transferred to a cryoprotectant solution (30% w/v
sucrose, 0.1% w/v sodium azide in PBS).
Spinal cords were frozen in O.C.T. embedding medium
(VWR, UK) and 14 μm serial sections were cut onto Super-
frost Plus slides (VWR) using a cryostat (CM3050S, Leica
Microsystems, UK Ltd). Sections were air dried and then
treated with 3% hydrogen peroxide in PBS for 30 minutes
at room temperature, washed with PBS and then blocked
with 5% normal goat serum (Sigma, UK) in PBS/0.2% Tri-
ton X-100. They were then incubated overnight with
mouse monoclonal anti-OX-42 (AbD Serotec, UK),
diluted 1:1000 in PBS/0.2% Triton X-100. This antibody
recognizes the complement receptor type 3(CR3) and spe-
cifically labels the plasma membrane of the microglial
cells. Sections were washed in PBS and incubated with a
biotinylated goat anti-mouse IgG secondary (Vector Lab-
oratories, UK) diluted 1:500 in PBS/0.2% Triton X-100 for
2 hours at RT. They were washed again, treated with avi-
din-biotin complex (Vector Laboratories, UK) according
to the manufacturer's instructions, rinsed again and incu-
bated with diaminobenzidine/nickel (Vector Laborato-
ries, UK). The reaction was stopped with PBS and slides
were dehydrated and coverslipped. Sections obtained
from the eight rats were processed at the same time, and
the experiments were repeated three times. Images were
acquired using a Leica DMRA2 microscope (Leica, Nuss-
loch, Germany), and digital images were captured using a
Retiga 1300 12-bit camera (QImaging, Burnaby, BC, Can-
ada) and QCapture 1.1.6 software (QImaging) running
on a Macintosh G4 computer. Images were then assem-
bled into figures using Photoshop 7.0 (Adobe Systems,
San Jose, CA). OX-42 optical density was analysed at the
level of L4, L5 and L6. To quantify, we applied Image J
Software based analysis: nine equivalent boxes (areas of
interest, measuring 180 × 180 squared μm) were placed
within each dorsal horn covering the medial to lateral
extent of Rexed laminae I-V, and the mean grey saturation
measured within each area of interest. The mean value of
three equivalent boxes outside each section was then sub-
tracted to normalize background. Three sections were ana-
lysed at each level. Results (mean ± SEM) are expressed as
arbitrary units.
AEA and PEA hydrolysis in microglial cells in vitro
The AEA/PEA hydrolysis assay was based on Paylor et al.
[44]. In brief, BV2 mouse microglial cells (a generous gift
from N. Stella, University of Washington), passage
number <8, grown to confluency in 24 well plates were
pre-incubated for 10 min at 37°C in 400 μl HEPES-con-
taining physiological buffer, pH 8.0, containing 0.1%
fatty acid-free bovine serum albumin. The reaction was
initiated by the addition of 250 nM AEA or PEA contain-
ing [3H]-AEA or [3H]-PEA (approx 60,000 dpm/well),
respectively. After varying periods of incubation (2 to 30
minutes) at 37°C, the buffer was rapidly removed by aspi-
ration and replaced with 400 μl ice-cold methanol. Wells
were scraped and the entire contents of each well col-
lected. Following additions of 400 μl chloroform and 200
μl H2O, the phases were separated by centrifugation at
5,000 g for 2 minutes. Radioactivity in an aliquot of the
aqueous, upper phase containing [3H]-ethanolamine was
quantified by liquid scintillation spectroscopy.
Data analysis
Behavioural data were statistically analysed using two-way
ANOVA with treatment and time as factors, followed by
Bonferroni's post-hoc test, and are presented as mean ±
SEM of mechanical PWT in grams. Levels of ECs and
related compounds were calculated as the ratio of the EC
peak area with its internal standard on the chromatogram
and are expressed as mol/g wet weight of tissue. Levels of
ECs and related compounds were excluded from analysis
if the value was greater than 2 standard deviations from
the mean, giving n = 6 for all groups except: n = 5 for con-
tralateral vehicle-saline and ipsilateral vehicle-sham. Ipsi-Molecular Pain 2009, 5:35 http://www.molecularpain.com/content/5/1/35
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lateral and contralateral spinal cord levels of AEA, 2-AG,
OEA and PEA were statistically compared using a Mann-
Whitney test and are presented as mean % of contralateral
spinal cord values, or raw mean ± SEM). For comparison
of levels of AEA, 2-AG, OEA and PEA between treatment
groups, data were statistically compared using Kruskal-
Wallis test. Immunohistochemical data were analysed
using the Kruskal-Wallis non-parametric test and are pre-
sented as mean ± SEM of density of OX-42 staining.
Hydrolysis of AEA & PEA was expressed as pmoles/well
and was analysed as means ± SEM from six different cell
passages investigated in triplicate.
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